@article{e2e0c633fd1444aeaa0bd096896fd247,
title = "Insight and subjective measures of quality of life in chronic schizophrenia",
abstract = "Lack of insight is a well-established phenomenon in schizophrenia, and has been associated with reduced rater-assessed functional performance but increased self-reported well-being in previous studies. The objective of this study was to examine factors that might influence insight (as assessed by the Insight and Treatment Attitudes Questionnaire [ITAQ] or PANSS item G12) and subjective quality-of-life (as assessed by Lehman QoL Interview [LQOLI]), using the large National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) dataset. Uncooperativeness was assessed by PANSS item G8 ({"}Uncooperativeness{"}). In the analysis, we found significant moderating effects for insight on the relationships of subjective life satisfaction assessment to symptom severity (as assessed by CGI-S score), objective everyday functioning (as assessed by rater-administered Heinrichs-Carpenter Quality of Life scale), clinically rated uncooperativeness (as assessed by PANSS G8), and discontinuation of treatment for all causes (all P. <. 0.05 for statistical interaction between insight and subject QoL). Patients with chronic schizophrenia who reported being {"}pleased{"} or {"}delighted{"} on LQOLI were found to have significantly lower neurocognitive reasoning performance and poorer insight (ITAQ total score). Our findings underscore the importance of reducing cognitive and insight impairments for both treatment compliance and improved functional outcomes.",
keywords = "Insight into illness, Neurocognition, Patient-rated quality of life, Schizophrenia, Subjective well-being",
author = "Siu, {Cynthia O.} and Harvey, {Philip D.} and Ofer Agid and Mary Waye and Carla Brambilla and Choi, {Wing Kit} and Gary Remington",
note = "Funding Information: Dr. Siu serves as a consultant for Sunovion Pharmaceuticals Inc. and Pfizer Inc. Dr. Harvey serves as a consultant/advisory board member for Boeheringer-Ingelheim, Forum Pharma, Genentech, Otsuka-America, Roche Pharma, Sanofi, Sunovion, and Takeda. Dr. Remington has received research support from the Canadian Diabetes Association, the Canadian Institutes of Health Research, Medicure, Neurocrine Biosciences, Novartis, Research Hospital Fund–Canada Foundation for Innovation, and the Schizophrenia Society of Ontario and has served as a consultant or speaker for Novartis, Laboratorios Farmac{\'e}uticos Rovi, Synchroneuron, and Roche. Dr. Agid has served on Advisory Board of Janssen-Ortho (Johnson and Johnson); Sepracor, Sunovion, Roche, Novartis, BMS, Otsuka, Lundbeck; Speaking engagements for Janssen-Ortho (Johnson and Johnson); Novartis; SepracorInc.,US.; Sunovion, Lundbeck.; and research Contracts for Pfizer, Inc., Janssen-Ortho (Johnson and Johnson), and Otsuka. Drs. Waye, Brambilla and Choi have declared no conflict of interest. Funding Information: None. Dr. Harvey is supported by NIMH grant number 1 RO1 MH93432 . Funding Information: Data used in the preparation of this article were obtained from the limited access datasets distributed from the NIH-supported “ Clinical Antipsychotic Trials of Intervention Effectiveness in Schizophrenia” (CATIE-Sz). This is a multisite, clinical trial of persons with schizophrenia comparing the effectiveness of randomly assigned medication treatment. The CATIE-Sz study was supported by NIMH Contract # N01MH90001 to the University of North Carolina at Chapel Hill. The ClinicalTrials.gov identifier is NCT00014001. Publisher Copyright: {\textcopyright} 2015.",
year = "2015",
month = sep,
day = "1",
doi = "10.1016/j.scog.2015.05.002",
language = "English (US)",
volume = "2",
pages = "127--132",
journal = "Schizophrenia Research: Cognition",
issn = "2215-0013",
publisher = "Elsevier Inc.",
number = "3",
}